Literature DB >> 2831247

In vitro corticotropin-releasing hormone (CRH) stimulation of adrenocorticotropin release from corticotroph adenoma cells: effect of prolonged exposure to CRH and its interaction with cortisol.

M Grino1, F Boudouresque, B Conte-Devolx, G Gunz, F Grisoli, C Oliver, P Jaquet.   

Abstract

To examine if down-regulation of CRH-induced ACTH release occurs in corticotroph adenoma cells as well as CRH-glucocorticoid interactions in these cells, we established primary cultures of pituitary adenoma cells obtained by transphenoidal surgery from five patients with Cushing's disease. To prevent binding of glucocorticoids by serum proteins, we used a serum-free medium containing insulin, transferrin, selenium, and epidermal growth factor. The latter was found to be essential for both basal and CRH-stimulated ACTH secretion. CRH acutely stimulated, in a dose-dependent manner, ACTH release by all adenomas studied, with an IC50 of 0.5 X 10(-9) mol/L. Prolonged exposure (10 days) to a half-maximal stimulatory concentration of CRH led to continuous stimulation of ACTH secretion. A 4-day incubation with cortisol induced a dose-dependent decrease in both basal and long term CRH-stimulated ACTH release, with no difference in the IC50 (1 X 10(-8) mol/L). These data suggest that long term exposure to CRH does not desensitize corticotroph adenoma cells. Thus, it is unlikely that long-acting analogs of CRH will be useful in the treatment of Cushing's disease. ACTH secretion from corticotroph adenomas is restrained by glucocorticoids; the sensitivity of these cells to the negative effect of glucocorticoids is not modified by long term stimulation with CRH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831247     DOI: 10.1210/jcem-66-4-770

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

Review 2.  Medical management of pituitary adenomas: structural and ultrastructural changes.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Normalized Early Postoperative Cortisol and ACTH Values Predict Nonremission After Surgery for Cushing Disease.

Authors:  David Asuzu; Grégoire P Chatain; Christina Hayes; Sarah Benzo; Raven McGlotten; Meg Keil; Andrea Beri; Susmeeta T Sharma; Lynnette Nieman; Maya Lodish; Constantine Stratakis; Russell R Lonser; Edward H Oldfield; Prashant Chittiboina
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

4.  Earlier post-operative hypocortisolemia may predict durable remission from Cushing's disease.

Authors:  Natasha Ironside; Gregoire Chatain; David Asuzu; Sarah Benzo; Maya Lodish; Susmeeta Sharma; Lynnette Nieman; Constantine A Stratakis; Russell R Lonser; Prashant Chittiboina
Journal:  Eur J Endocrinol       Date:  2018-01-12       Impact factor: 6.664

Review 5.  Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations.

Authors:  Eleni Daniel; John Newell-Price
Journal:  F1000Res       Date:  2017-05-02

6.  An activating mutation in the CRHR1 gene is rarely associated with pituitary-dependent hyperadrenocorticism in poodles.

Authors:  Viviani De-Marco; Luciani R Carvalho; Mariana F Guzzo; Paulo S L Oliveira; Larissa G Gomes; Berenice B Mendonca
Journal:  Clinics (Sao Paulo)       Date:  2017-10       Impact factor: 2.365

7.  Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas.

Authors:  Maria Francesca Cassarino; Antonella Sesta; Luca Pagliardini; Marco Losa; Giovanni Lasio; Francesco Cavagnini; Francesca Pecori Giraldi
Journal:  Endocrine       Date:  2016-05-24       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.